Morgan Stanley reports that third party data reveals a 22% year-over-year decline for Hims & Hers app downloads in the month of August, giving the company a four-month streak of negative growth and a decline for the sixth time in seven months. A key debate for the stock is slowing growth in the core offering and durability of growth in weight loss relative to contributions from new product introductions, such as the new testosterone offering, says the analyst. These dynamics are likely to keep Hims volatile, adds the analyst, who has an Equal Weight rating and $40 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- FDA chief says Hims & Hers Super Bowl ad violated drug promotion rules
- Time to Bet on Hims & Hers Health (HIMS)? Analysts Point to Several Growth Catalysts
- Hims & Hers Health Stock Surges Amid Mixed Analyst Views
- Cautious Outlook on Hims & Hers Health Amidst Regulatory Changes and Increased Volatility
- Sell Recommendation for Hims & Hers Health Due to Modest Revenue Expectations and High Marketing Costs